These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30689581)

  • 1. Novel Blood Biomarkers that Correlate with Cognitive Performance and Hippocampal Volumetry: Potential for Early Diagnosis of Alzheimer's Disease.
    Hudd F; Shiel A; Harris M; Bowdler P; McCann B; Tsivos D; Wearn A; Knight M; Kauppinen R; Coulthard E; White P; Conway ME
    J Alzheimers Dis; 2019; 67(3):931-947. PubMed ID: 30689581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple and clinically relevant combination of neuroimaging and functional indexes for the identification of those at highest risk of Alzheimer's disease.
    Tabatabaei-Jafari H; Walsh E; Shaw ME; Cherbuin N;
    Neurobiol Aging; 2018 Sep; 69():102-110. PubMed ID: 29864716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive/Functional Measures Predict Alzheimer's Disease, Dependent on Hippocampal Volume.
    Tabatabaei-Jafari H; Shaw ME; Walsh E; Cherbuin N
    J Gerontol B Psychol Sci Soc Sci; 2020 Aug; 75(7):1393-1402. PubMed ID: 30668830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma d-glutamate levels for detecting mild cognitive impairment and Alzheimer's disease: Machine learning approaches.
    Chang CH; Lin CH; Liu CY; Huang CS; Chen SJ; Lin WC; Yang HT; Lane HY
    J Psychopharmacol; 2021 Mar; 35(3):265-272. PubMed ID: 33586518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study: visual rating scores and the voxel-based specific regional analysis system for Alzheimer's disease on magnetic resonance imaging among subjects with Alzheimer's disease, mild cognitive impairment, and normal cognition.
    Li F; Takechi H; Saito R; Ayaki T; Kokuryu A; Kuzuya A; Takahashi R
    Psychogeriatrics; 2019 Mar; 19(2):95-104. PubMed ID: 30276926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. D-glutamate, D-serine, and D-alanine differ in their roles in cognitive decline in patients with Alzheimer's disease or mild cognitive impairment.
    Lin CH; Yang HT; Lane HY
    Pharmacol Biochem Behav; 2019 Oct; 185():172760. PubMed ID: 31422081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
    de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
    J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer's disease.
    Olazarán J; Gil-de-Gómez L; Rodríguez-Martín A; Valentí-Soler M; Frades-Payo B; Marín-Muñoz J; Antúnez C; Frank-García A; Acedo-Jiménez C; Morlán-Gracia L; Petidier-Torregrossa R; Guisasola MC; Bermejo-Pareja F; Sánchez-Ferro Á; Pérez-Martínez DA; Manzano-Palomo S; Farquhar R; Rábano A; Calero M
    J Alzheimers Dis; 2015; 45(4):1157-73. PubMed ID: 25649659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers.
    Dukart J; Sambataro F; Bertolino A
    J Alzheimers Dis; 2016; 49(4):1143-59. PubMed ID: 26599054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-Term Practice Effects on Cognitive Tests Across the Late Life Cognitive Spectrum and How They Compare to Biomarkers of Alzheimer's Disease.
    Duff K; Hammers DB; Koppelmans V; King JB; Hoffman JM
    J Alzheimers Dis; 2024; 99(1):321-332. PubMed ID: 38669544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher Peripheral TREM2 mRNA Levels Relate to Cognitive Deficits and Hippocampal Atrophy in Alzheimer's Disease and Amnestic Mild Cognitive Impairment.
    Tan YJ; Ng ASL; Vipin A; Lim JKW; Chander RJ; Ji F; Qiu Y; Ting SKS; Hameed S; Lee TS; Zeng L; Kandiah N; Zhou J
    J Alzheimers Dis; 2017; 58(2):413-423. PubMed ID: 28453482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between hippocampal subfield volumes in mild cognitive impairment and conversion to Alzheimer's disease.
    Izzo J; Andreassen OA; Westlye LT; van der Meer D
    Brain Res; 2020 Feb; 1728():146591. PubMed ID: 31816319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomics based identification of differential plasma proteins and changes in white matter integrity as markers in early detection of mild cognitive impaired subjects at high risk of Alzheimer's disease.
    Kumar A; Singh S; Verma A; Mishra VN
    Neurosci Lett; 2018 May; 676():71-77. PubMed ID: 29649488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlations between cerebellar and brain volumes, cognitive impairments, ApoE levels, and APOE genotypes in patients with AD and MCI.
    Łojkowska W; Witkowski G; Bednarska-Makaruk M; Wehr H; Sienkiewicz-Jarosz H; Graban A; Bochyńska A; Wiśniewska A; Gugała M; Sławińska K; Sawicka B; Poniatowska R; Ryglewicz D
    Curr Alzheimer Res; 2013 Nov; 10(9):964-72. PubMed ID: 24117117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.
    Espinosa A; Alegret M; Pesini P; Valero S; Lafuente A; Buendía M; San José I; Ibarria M; Tejero MA; Giménez J; Ruiz S; Hernández I; Pujadas F; Martínez-Lage P; Munuera J; Arbizu J; Tárraga L; Hendrix SB; Ruiz A; Becker JT; Landau SM; Sotolongo-Grau O; Sarasa M; Boada M; ;
    J Alzheimers Dis; 2017; 57(2):447-459. PubMed ID: 28269787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset.
    Johnstone D; Milward EA; Berretta R; Moscato P;
    PLoS One; 2012; 7(4):e34341. PubMed ID: 22485168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
    Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
    Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting the conversion of mild cognitive impairment to Alzheimer's disease based on the volumetric measurements of the selected brain structures in magnetic resonance imaging.
    Nesteruk M; Nesteruk T; Styczyńska M; Barczak A; Mandecka M; Walecki J; Barcikowska-Kotowicz M
    Neurol Neurochir Pol; 2015; 49(6):349-53. PubMed ID: 26652867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.